课题基金 / 基金详情

BREAST CANCER PREVENTION IN HODGKINS DISEASE

BREAST CANCER PREVENTION IN HODGKINS DISEASE
霍奇金病中的乳腺癌预防
批准号:
6514642
负责人:
JUDY E. GARBER
金额:
$12.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-06-29 至 2004-05-31

项目摘要

项目成果

JUDY E. GARBER的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(申请人的描述) 霍奇金病具有良好的预后,大多数 治愈原发肿瘤的患者。然而,治疗的晚期并发症 在这些患者中,特别是新的原发性癌症, 在这一群体中,特别重要的是乳腺癌的风险增加, 在接受了斗篷或胸部手术的女性霍奇金病幸存者中, 放疗(RR约为20,治疗后15年)。他莫昔芬已 研究表明,在2000年, 根据Gail模型、DCIS或 既往乳腺癌II. 尚未在放射性乳腺癌中进行评价 癌HD幸存者也可能经历早期绝经,如果他们的HD治疗 包括化疗12例,早期动脉粥样硬化性心脏病13例,14例, 其他第二癌症的风险,从辐射或联合方式I。这些 这些担忧可能会影响他莫昔芬的风险/获益考虑, 风险在年轻时就变得明显的风险人群。因为这些 问题,似乎重要的是要证明,而不是假设,他莫昔芬 降低了这一人群患乳腺癌的风险。 然而,由于有一个 有限数量的妇女可用于足够规模的研究,以解决 这个问题有足够的力量,论证的可行性似乎 很危险在拟议的研究中,我们将讨论可行性问题, 包括招募/接受、依从性、毒性和生活质量, 和生殖激素状况我们计划招募50名女性霍奇金淋巴瘤患者 治疗包括放射治疗(地幔或其他)的疾病幸存者 胸部),在30岁之前诊断,当前年龄大于30岁, 超过8年的辐射参与一项试点研究,他们将 在研究中接受他莫昔芬2年,总共5年。 我们将 估计招募率,评估依从性,评估生活质量, 使用BCPT中采用的措施以及开发的问题 对于这个人口。我们的顾问委员会将考虑一年的数据, 帮助我们决定是否继续尝试更大的研究。一 如果符合以下条件,则在可用的HD幸存者中进行确定性随机试验是可行的 依从性为90例,基于估计的绝对风险为8 未服用他莫昔芬的女性患者5年内的不良反应。这是一个很大的风险 大于BCPT队列的平均风险,允许较小的 样本量我们还将评估乳房X线摄影密度作为一种潜在的 可能允许更快完成随机化的中间终点 study.
英文摘要
DESCRIPTION: (Applicant's Description) Hodgkin's Disease carries an excellent prognosis, with the majority of patients cured of their primary tumor. However, late complications of therapy in these patients are of increasing concern, especially new primary cancers of particular importance in this group is the increased risk of breast cancer among female Hodgkin's disease survivors who received mantle or chest radiation (RR approximate 20 by 15 yrs after treatment). Tamoxifen has been shown to reduce the risk of breast cancer by nearly 50percents in women at increased risk on the basis factors considered in the Gail model, DCIS or prior breast cancer II. It has not yet been evaluated in radiogenic breast cancer. HD survivors may also experience early menopause if their HD treatment included chemotherapy 12, and early atherosclerotic heart disease l3,14 and other second cancer risk from radiation or combined modalities I. These concerns may affect the risk/benefit considerations of tamoxifen in this high risk population whose risk becomes manifest at young ages. Because of these issues, it seems important to prove, rather than assume, that tamoxifen ireduces breast cancer risk in this population. However, since there are a limited number of women available for a study of sufficient size to address the question with sufficient power, demonstration of feasibility seems critical. In the proposed study, we will address aspects of feasibility , including recruitment/acceptance, adherence, toxicities and quality of life, and reproductive hormone status. We propose to recruit 50 female Hodgkin's Disease survivors whose treatment included radiation therapy (mantle or other chest), diagnosed before age 30, current age greater than 30 years, greater than 8 years from radiation to participate in a pilot study in which they will receive tamoxifen for 2 years on study, and 5 years in total. We will estimate recruitment rates, evaluate adherence, and assess quality of life and toxicities using measures employed in the BCPT, as well as questions developed for this population. Our advisory board will consider the one year data and assist us in deciding whether or not to proceed to attempt the larger study. A definitive randomized trial would be feasible with available HD survivors if adherence were 90 percents, based upon an estimated absolute risk of 8 percents over a 5 year period in women without tamoxifen. This is a risk much greater than the average risk in the BCPT cohort, permitting the smaller sample size. We will also evaluate mammographic density as a potential intermediate endpoint that might permit more rapid completion of a randomized study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Career Enhancement Program
  • 批准号:
    10455696
  • 项目类别:
  • 资助金额:
    $15.75万
  • 财政年份:
    2013
  • 负责人:
    JUDY E. GARBER
  • 依托单位:
Career Enhancement Program
  • 批准号:
    10215419
  • 项目类别:
  • 资助金额:
    $17.78万
  • 财政年份:
    2013
  • 负责人:
    JUDY E. GARBER
  • 依托单位:
Career Enhancement Program
  • 批准号:
    10668351
  • 项目类别:
  • 资助金额:
    $16.51万
  • 财政年份:
    2013
  • 负责人:
    JUDY E. GARBER
  • 依托单位:
PILOT STUDY OF AROMATASE INHIBITORS
  • 批准号:
    7719307
  • 项目类别:
  • 资助金额:
    $0.19万
  • 财政年份:
    2008
  • 负责人:
    JUDY E. GARBER
  • 依托单位:
海外基金